Mitochondrials complex I activity is reduced in latent adriamycin-induced cardiomyopathy of rat.
We previously reported on the use of enzymatic analysis to impair fatty acid metabolism followed by reduced myocardial energy content, leading to severe heart failure in adriamycin (ADR)-treated rats. The aim of this study is to investigate whether impaired myocardial energy metabolism can also be detected by other methods; i.e. measuring mitochondrial complex I activity and myocardial 125I-15-(p-iodophenyl)-3-(R,S)- methylpentadecanoic acid (BMIPP) accumulation in ADR-treated rats. Eight-week-old male Sprague-Dawley rats received 6 intraperitoneal injections of ADR (total 15 mg/kg: group ADR) or saline (control group) over 2 weeks. Left ventricular (LV) ejection fraction was assessed using echocardiography at 3- and 6-weeks after ADR injection (3 weeks and 6 weeks, respectively). Myocardial fatty acid utilization was assessed at 3 weeks and 6 weeks. The myocardial counts of BMIPP were measured after intravenous BMIPP (370 kBq) injection, and 125I counts were measured to calculate the uptake ratio. The enzymatic activity of complex I was assessed by monitoring the oxidation of nicotinamide-adenine-dinucleotide-disodium-salt (NADH). In rats treated with ADR, significant decrease in LV ejection fraction was observed only at 6 weeks compared to control (72.5 vs. 84.5%, p < 0.01). LV ejection fraction at 3 weeks was identical between group ADR and control (81.8 vs. 84.4%). However, at 3 weeks, complex I activity was already reduced significantly in group ADR as compared to control group (p = 0.03), but the reduction in BMIPP accumulation was not (p = 0.15). Our data indicated that reduced complex I activity in a phenomenon occurred in early phase of ADR-induced cardiomyopathy, and it might play an important role in the progression of ADR-induced heart failure.
Ohkura
Kiyotaka
K
First Department of Internal Medicine, Fukui Medical University, Shimoaizuki, Matsuoka-cho, Fukui, Japan.
Lee
Jong-Dae
JD
Shimizu
Hiromasa
H
Nakano
Akira
A
Uzui
Hiroyasu
H
Horikoshi
Motosaburo
M
Fujibayashi
Yasuhisa
Y
Yonekura
Yoshiharu
Y
Ueda
Takanori
T
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001835:Body Weight; D009202:Cardiomyopathies / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D004317:Doxorubicin / Q000494:pharmacology*; D004452:Echocardiography; D005227:Fatty Acids / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D006339:Heart Rate; D006352:Heart Ventricles / Q000473:pathology; D007462:Iodobenzenes / Q000493:pharmacokinetics / Q000494:pharmacology; D008297:Male; D008928:Mitochondria / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D010100:Oxygen / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
D000903:Antibiotics, Antineoplastic; D005227:Fatty Acids; D007462:Iodobenzenes; C049338:iodofiltic acid; D009243:NAD; D004317:Doxorubicin; C067799:4-iodophenyl-9-methylpentadecanoic acid; D010100:Oxygen